MIP Discovery Rebrands as Tozaro Completing Transition to Support Viral Vector Analysis and Cell and Gene Therapy Purification

MIP Discovery Rebrands as Tozaro Completing Transition to Support Viral Vector Analysis and Cell and Gene Therapy Purification

MIP Discovery today announced the company's rebrand to Tozaro, completing its transition to becoming a technology innovator in the Cell and GT Therapy (CGT) bioprocessing sector.

The rebrand comes at a time of significant growth for the company following its mission to improve downstream processing within the CGT. The company's updated brand identity fully supports this change in focus and reinforces its commitment to enable innovation within CGT bioprocessing with its Smart Polymer technology.

Tozaro's smart polymers are uniquely and rationally designed using computational chemistry to create novel affinity solutions that allow users to push the boundaries of what is currently possible with biological reagents. As part of the design process, whole viruses are evaluated to identify unique surface epitopes for binding synthetic affinity reagents. A library of over 600 monomers (the building blocks of smart polymers) will be screened against the identified epitopes to select those with optimal characteristics for the development of new smart polymers. The chemical manufacturing process gives control over specific characteristics such as affinity to the virus and allows fine-tuning to specific application requirements in analysis and purification. This, combined with the scalability and safety profile of non-biological affinity reagents, provides new solutions for those developing essential viral vector purification and analytical tools.

"The promise of cell and gene therapies is limited by the high costs of producing treatments using inefficient and cumbersome methods. Tozaro's novel approach to building reagents for viral vector production can change this."said Dr. Mike Evans, Chairman of the Board, Tozaro.“The rebranding, including a name change to Tozaro, aligns with our continued commitment to growth and focus on developing novel solutions that enable widespread adoption of next-generation therapies.”

Guy Leaver, interim CEO, told Tozaro:"We have already seen positive results with our first wave of Lentivirus Smart polymers designed for both analytics and capture chromatography. We are pleased to see this trend continue as we enter the latter part of the year and expand our portfolio under our new Tozaro identity."

To learn more about how Tozaro is enabling cell and gene therapy developers, please visit www.tozaro.com

Sources: